Vaccine effectiveness estimates from an early-season influenza A(H3N2) epidemic, including unique genetic diversity with reassortment, Canada, 2022/23

The Canadian Sentinel Practitioner Surveillance Network estimated vaccine effectiveness (VE) during the unusually early 2022/23 influenza A(H3N2) epidemic. Like vaccine, circulating viruses were clade 3C.2a1b.2a.2, but with genetic diversity affecting haemagglutinin positions 135 and 156, and reassortment such that H156 viruses acquired neuraminidase from clade 3C.2a1b.1a. Vaccine provided substantial protection with A(H3N2) VE of 54% (95% CI: 38 to 66) overall. VE was similar against H156 and vaccine-like S156 viruses, but with potential variation based on diversity at position 135.

[1]  N. Bastien,et al.  National influenza mid-season report, 2022-2023: A rapid and early epidemic onset. , 2023, Canada communicable disease report = Releve des maladies transmissibles au Canada.

[2]  M. Valenciano,et al.  Influenza vaccine effectiveness against influenza A subtypes in Europe: Results from the 2021–2022 I‐MOVE primary care multicentre study , 2022, Influenza and other respiratory viruses.

[3]  C. Bancej,et al.  National Influenza Annual Report, Canada, 2021–2022: A brief, late influenza epidemic , 2022, Canada Communicable Disease Report.

[4]  A. Monto,et al.  Influenza Vaccine Effectiveness Against Influenza A(H3N2)-Related Illness in the United States During the 2021-2022 Influenza Season , 2022, medRxiv.

[5]  D. Skowronski,et al.  Influenza vaccine effectiveness against A(H3N2) during the delayed 2021/22 epidemic in Canada , 2022, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[6]  Aman Verma,et al.  Effects of Confounding Bias in Coronavirus Disease 2019 (COVID-19) and Influenza Vaccine Effectiveness Test-Negative Designs Due to Correlated Influenza and COVID-19 Vaccination Behaviors , 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  Manish M Patel,et al.  Role of Age in Spread of Influenza, 2011-2019, U.S. Influenza Vaccine Effectiveness Network. , 2021, American journal of epidemiology.

[8]  D. Skowronski,et al.  Influenza Vaccine Effectiveness by A(H3N2) Phylogenetic Subcluster and Prior Vaccination History: 2016–2017 and 2017–2018 Epidemics in Canada , 2020, The Journal of infectious diseases.

[9]  Mel Krajden,et al.  Influenza Classification Suite: An automated Galaxy workflow for rapid influenza sequence analysis , 2020, Influenza and other respiratory viruses.

[10]  M. Valenciano,et al.  Low 2018/19 vaccine effectiveness against influenza A(H3N2) among 15–64-year-olds in Europe: exploration by birth cohort , 2019, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[11]  D. Skowronski,et al.  Paradoxical clade- and age-specific vaccine effectiveness during the 2018/19 influenza A(H3N2) epidemic in Canada: potential imprint-regulated effect of vaccine (I-REV) , 2019, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[12]  John Huddleston,et al.  Evolution and rapid spread of a reassortant A(H3N2) virus that predominated the 2017-2018 influenza season. , 2019, Virus evolution.

[13]  M. E. Francis,et al.  Back to the Future for Influenza Preimmunity—Looking Back at Influenza Virus History to Infer the Outcome of Future Infections , 2019, Viruses.

[14]  Yuelong Shu,et al.  GISAID: Global initiative on sharing all influenza data – from vision to reality , 2017, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[15]  D. Burke,et al.  Substitutions Near the Receptor Binding Site Determine Major Antigenic Change During Influenza Virus Evolution , 2013, Science.

[16]  Louise Pelletier,et al.  Age-specific Differences in Influenza A Epidemic Curves: Do Children Drive the Spread of Influenza Epidemics? , 2011, American journal of epidemiology.

[17]  Yoshihiro Kawaoka,et al.  Single-Reaction Genomic Amplification Accelerates Sequencing and Vaccine Production for Classical and Swine Origin Human Influenza A Viruses , 2009, Journal of Virology.

[18]  N. Wingreen,et al.  Differential neutralization efficiency of hemagglutinin epitopes, antibody interference, and the design of influenza vaccines , 2009, Proceedings of the National Academy of Sciences.

[19]  M. Schemper,et al.  A solution to the problem of separation in logistic regression , 2002, Statistics in medicine.

[20]  D. Firth.  Bias reduction of maximum likelihood estimates , 1993 .